Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

NCT06406153 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Mucopolysaccharidosis Type 1

Interventions

BIOLOGICAL: Laronidase
DRUG: Antihistamine
DRUG: Antipyretic

Sponsor

Cinnagen